Product Development Progress - The company announced that its self-developed breast cancer NGS companion diagnostic kit has successfully entered the priority review channel of the National Medical Products Administration (NMPA) Medical Device Technology Review Center (CMDE), which may accelerate the approval process for the product in the domestic market [2] Financial Performance - According to the Q2 2025 financial report released on September 8, 2025, the company achieved a revenue growth of 10% year-on-year, with net losses narrowing by 91%. The gross margin improved to 72.8%, indicating significant operational efficiency improvements [3] Stock Performance - On January 5, 2026, the company's stock price experienced a notable increase, rising by 6.71% in a single day, closing at $21.00 per share [4]

Core Viewpoint - The breast cancer NGS companion diagnostic kit developed by the company has entered the priority review channel of the National Medical Products Administration (NMPA), which will shorten the approval cycle for the product in China [1]. Product Development Progress - The entry of the diagnostic kit into the priority review channel is a significant technological advancement worth noting [2].